Introduction
============

Community-acquired pneumonia (CAP) remains a serious illness and a major cause of death. Former studies have shown that in patients with CAP, systemic inflammatory responses lead to poor clinical outcomes.[@b1-ijgm-6-693],[@b2-ijgm-6-693] Therefore, attenuating systemic inflammatory responses is occasionally attempted in severe CAP. Corticosteroids are well known as anti-inflammatory agents and act at the genomic level.

In severe sepsis and septic shock, there is growing evidence that low-dose systemic corticosteroids may contribute to favorable clinical outcomes.[@b3-ijgm-6-693],[@b4-ijgm-6-693] However, in CAP, the efficacy of systemic corticosteroids added to antibiotic therapy has not yet been confirmed. In a retrospective study, Garcia-Vidal et al reported that the administration of systemic corticosteroids contributed to the reduction of mortality in severe CAP.[@b5-ijgm-6-693] In contrast, the randomized, double-blind, placebo-controlled study produced by Snijders et al showed no beneficial effects of adjunctive corticosteroids in hospitalized CAP patients.[@b6-ijgm-6-693]

Most of the previous placebo-controlled interventional CAP studies included a limited number of critically ill patients.[@b6-ijgm-6-693]--[@b9-ijgm-6-693] Therefore, the impact of adjunctive systemic corticosteroids on the prognosis of CAP has not yet been revealed. In current clinical practice, systemic corticosteroids are often added to the initial administration of antibiotics in some cases of very severe CAP, depending on the discretion of each pulmonologist.

In this single-center, prospective, and observational study, we investigated the clinical features of patients treated with early adjunctive systemic corticosteroids and impact of early adjunctive systemic corticosteroids on clinical outcomes in very severe CAP.

Materials and methods
=====================

Patients
--------

Consecutive patients admitted to the Ichinomiya-Nishi hospital (a 400-bed teaching hospital in Ichinomiya City, Aichi, Japan) because of CAP, from August 2010 through February 2013, who had a pneumonia severity index (PSI) of \>130 points (class 5)[@b10-ijgm-6-693] on admission, were enrolled in this study. CAP was diagnosed in patients aged ≥18 years who were admitted from the community or a nursing home, had not been hospitalized in the 90 days before the start of the study, did not have any antibiotic exposure during the 14 days prior to enrollment, presented with a new radiographic infiltrate, and who showed at least two compatible clinical symptoms (body temperature \>38°C, productive cough, chest pain, shortness of breath, or crackles on auscultation). Patients were excluded if they were chronically immunosuppressed (chemotherapy, human immunodeficiency virus infection, therapy with corticosteroids, or other immunosuppressive agents).

Informed consent was obtained from all patients, according to the hospital's guidelines. This study protocol and consent procedure followed the statements of the Declaration of Helsinki, and was approved by the ethics committee of our hospital, called the Research Ethics Review Committee of Ichinomiya-Nishi Hospital (Study Number 25011).

Methods and endpoints
---------------------

Calculation of PSI, collection of venous blood samples, arterial blood gas analysis, microbiological sputum examination, and urinary antigen tests for *Streptococcus pneumoniae* (Alere BinaxNOW® S pneumoniae Antigen Card; Alere Inc, Waltham, MA, USA) and *Legionella pneumophila* serogroup 1 (Alere BinaxNOW® Legionella Urinary Antigen Card; Alere Inc) were performed on admission for all CAP patients. Measurements of blood counts and levels of serum biochemical markers (C-reactive protein \[CRP\], blood urea nitrogen, albumin, glucose, sodium, and creatinine) were performed immediately after blood sampling. Serum CRP level was measured using a latex agglutination assay (N-Assay LA CRP-S, Nittobo Medical, Tokyo, Japan). Other biochemical markers were assayed using standard methods. Causative pathogens were diagnosed with the finding of 3+ growth in the sputum culture or the presence of antigen in urine.

Coexisting illnesses (heart failure, diabetes mellitus, cerebrovascular diseases, neoplastic diseases, chronic kidney diseases, advanced liver diseases, chronic obstructive pulmonary disease \[COPD\], and other lung diseases) were assessed by the treating pulmonologists.

Performance status before admission was evaluated according to the European Cooperative Oncology Group score.[@b11-ijgm-6-693] The grades were defined as follows: grade 0 = fully active, able to carry on all predisease performance without restriction; grade 1 = restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature; grade 2 = ambulatory and capable of all self-care but unable to carry out any work activity, up and about more than 50% of working hours; grade 3 = capable of only limited self-care, confined to bed or chair more than 50% of working hours; and grade 4 = completely disabled, cannot carry on any self-care, totally confined to bed or chair.

The choice of antibiotic regimen was made according to the national guidelines proposed by the Japanese Respiratory Society.[@b12-ijgm-6-693] The administration of systemic corticosteroids was left to the discretion of each treating pulmonologist. Treatment with early adjunctive systemic corticosteroids was defined as administration of dosages equivalent to prednisone of ≥20 mg/day, which is considered as a "stress dose" of systemic corticosteroids for pneumonia,[@b13-ijgm-6-693] added to the initial intravenous antibiotic medication.

The primary endpoint of this study was mortality within 28 days of admission. The secondary endpoints were requirement for intensive care and occurrence of adverse events. Requirement for intensive care was defined as the use of mechanical ventilation or vasopressors against shock. Adverse events were defined as hyperglycemia with requirement for additional glucose-lowering therapy, confusion, nosocomial infection, or gastrointestinal bleeding.

Statistical analysis
--------------------

The data were expressed as numbers or medians (25th--75th percentile range). The differences between the two groups were tested using the nonparametric Mann--Whitney *U* test for continuous variables and Fisher's exact test for categorical variables. Survival curves from admission were plotted using the Kaplan-Meier method, and the comparison between two curves was performed using the logrank test. To investigate the independent factors associated with mortality, multivariate analysis was performed using the Cox proportional hazard model. The variables incorporated in the multivariate analysis were the factors significantly associated with mortality at the 0.20 level in univariate analysis. The results were expressed as hazard ratio (HR) and 95% confidence interval (CI). A two-tailed probability value \<0.05 was considered to be statistically significant.

Results
=======

Patient population
------------------

During the study period, a total of 469 patients were admitted because of CAP. Of these, 103 had a PSI score of \>130 points on admission. Two patients were excluded because of immunosuppression. Thus finally, 101 patients having \>130 points of PSI on admission were enrolled in this study ([Figure 1](#f1-ijgm-6-693){ref-type="fig"}).

The baseline characteristics of enrolled patients are shown in [Table 1](#t1-ijgm-6-693){ref-type="table"}. No one had advanced liver disease, while eight patients (7.9%) had chronic kidney disease. Fourteen patients (13.9%) had underlying lung diseases, including COPD (n = 11), bronchial asthma (n = 2), and chronic interstitial pneumonia (n = 1). Thirty-two patients (31.7%) died within 28 days of admission, and 45 patients (44.6%) needed intensive care. Causative pathogens were detected in 56 patients (55.4%) and are listed in [Table 2](#t2-ijgm-6-693){ref-type="table"}. The most frequently detected pathogen was *S. pneumoniae* (n = 17, 16.8%).

Indication for and impact of early adjunctive systemic corticosteroids
----------------------------------------------------------------------

Thirty patients (29.7%) were administered systemic corticosteroids added to their initial antibiotic medication. The dosages of adjunctive systemic corticosteroids are listed in [Table 3](#t3-ijgm-6-693){ref-type="table"}. The median dosage of early adjunctive systemic corticosteroids was 50 mg/day (30--50 mg/day) of an equivalent to prednisone. Most patients treated with early adjunctive systemic corticosteroids received a bolus intravenous infusion for a period shorter than 8 days.

The characteristics of patients treated with and without early adjunctive systemic corticosteroids are shown in [Table 4](#t4-ijgm-6-693){ref-type="table"}. Of physical findings on admission, the patients treated with early adjunctive systemic corticosteroids were more likely to have an alteration of mental status (80.0% versus 40.8%) (*P* \< 0.001) and requirement for high flow oxygen inhalation (66.7% versus 43.7%) (*P* = 0.049) than were those without early corticosteroids. Of laboratory findings, the patients treated with early adjunctive systemic corticosteroids were more likely to have lower leukocyte counts (10.4 × 10^9^ cells/L versus 12.1 × 10^9^ cells/L) (*P* = 0.039), lower sodium levels (137 mEq/L versus 139 mEq/L) (*P* = 0.031), and higher albumin levels (3.3 g/dL versus 3.0 g/dL) (*P* = 0.003). Of coexisting illnesses, the patients treated with early adjunctive systemic corticosteroids were more likely to have COPD (26.7% versus 4.2%) (*P* = 0.002) and other lung diseases (10.0% versus 0) (*P* = 0.024) and less likely to have cerebrovascular diseases (23.3% versus 49.3%) (*P* = 0.017). Of initial antibiotic regimens, the patients treated with early adjunctive systemic corticosteroids were more likely to receive fluoroquinolones (26.7% versus 8.5%) (*P* = 0.025). Of radiographic and microbiological findings, no significant differences were observed between the patients with and without early adjunctive systemic corticosteroids.

Concerning the clinical outcomes, mortality and the requirement for intensive care did not differ significantly between the patients treated with and without early adjunctive systemic corticosteroids.

Adverse events
--------------

The adverse events of patients treated with and without early adjunctive systemic corticosteroids are shown in [Table 5](#t5-ijgm-6-693){ref-type="table"}. There were no significant differences of any adverse event between the groups. Septic shock induced by urinary tract infection occurred in one patient treated without early corticosteroids after 15 days of admission, while the other nosocomial infections were recurrence of pneumonia. Fatal gastrointestinal bleeding occurred in one patient treated without early corticosteroids after 10 days of admission.

Factors associated with mortality
---------------------------------

A comparison of the characteristics of deceased and surviving patients is shown in [Table 6](#t6-ijgm-6-693){ref-type="table"}. The deceased patients were more likely to have needed intensive care (78.1% versus 29.0%) (*P* \< 0.001) than were the surviving patients. Of laboratory findings, the deceased patients were more likely to have higher CRP levels (18.78 mg/dL versus 10.79 mg/dL) (*P* = 0.017), higher blood urea nitrogen levels (39.8 mg/dL versus 31.0 mg/dL) (*P* = 0.016), and lower albumin levels (2.9 g/dL versus 3.2 g/dL) (*P* = 0.005). Of microbiological findings, the deceased patients were more likely to have an etiology of methicillin-resistant *Staphylococcus aureus* (18.8% versus 4.3%) (*P* = 0.027). Of initial antibiotic regimens, the deceased patients were more likely to receive antipseudomonal beta-lactam agents (93.8% versus 73.9%) (*P* = 0.03). Of physical findings, radiographic findings, and coexisting illnesses, no significant differences were observed between the deceased and surviving patients.

The Kaplan-Meier survival curves for mortality within 28 days of admission did not differ significantly between the patients treated with and without early adjunctive systemic corticosteroids (*P* = 0.098) ([Figure 2](#f2-ijgm-6-693){ref-type="fig"}).

The results of multivariate analysis for mortality are shown in [Table 7](#t7-ijgm-6-693){ref-type="table"}. Factors independently associated with mortality were blood urea nitrogen (HR 1.02, 95% CI 1.00--1.04) (*P* = 0.013), serum albumin level (HR 0.44, 95% CI 0.22--0.86) (*P* = 0.017), a requirement for intensive care (HR 4.93, 95% CI 1.75--13.87) (*P* = 0.003), and the therapy with early adjunctive systemic corticosteroids (HR 0.29, 95% CI 0.11--0.81) (*P* = 0.018).

Discussion
==========

The present study in very severe CAP showed that (1) the addition of systemic corticosteroids to initial antibiotics was more frequently observed in patients having alteration of mental status, serious respiratory failure or underlying lung diseases, and receiving fluoroquinolones as initial antibiotics; (2) the dosage of additional (to initial antibiotics) systemic corticosteroids was less than 60 mg/day of an equivalent to prednisone by bolus intravenous infusion for a period shorter than 8 days in most patients; (3) the occurrence of adverse events did not differ between the patients treated with and without early adjunctive systemic corticosteroids; and (4) the early adjunctive systemic corticosteroid was an independent protective factor for mortality.

Systemic inflammatory responses brought about by severe pneumonia cause critical conditions, such as respiratory failure and hypotension.[@b14-ijgm-6-693],[@b15-ijgm-6-693] Corticosteroids inhibit the expression and action of many cytokines involved in inflammatory responses by binding to their specific receptors, which are located in the cytoplasm of nearly all human cells.[@b16-ijgm-6-693] Therefore, systemic corticosteroids can suppress inflammatory responses in specific tissues as well as in the whole body. However, not many CAP studies have shown that adjunctive systemic corticosteroids reduce the risk of mortality.[@b6-ijgm-6-693]--[@b9-ijgm-6-693],[@b17-ijgm-6-693] A recent meta-analysis showed that the addition of systemic corticosteroids for treatment of pneumonia accelerated the resolution of symptoms but did not reduce the mortality.[@b18-ijgm-6-693] To our knowledge, only two CAP studies have shown the efficacy of systemic corticosteroids for reducing mortality.[@b5-ijgm-6-693],[@b19-ijgm-6-693] In order to assess the influence of adjunctive systemic corticosteroids on mortality, it is necessary to study critically ill CAP patients. In fact, in clinical practice, the administration of adjunctive systemic corticosteroids is taken into consideration for critically ill CAP patients. However, most of the earlier CAP studies included patients with a mild to moderate severity of illness. In the present study, we confined our study cohort to critically ill patients, as per PSI, which is regarded as a reliable severity indicator of CAP throughout the world.[@b20-ijgm-6-693]--[@b22-ijgm-6-693] This may be one of the reasons why our study showed favorable efficacy of systemic corticosteroids in reducing the risk of mortality in CAP patients.

It is not clear whether continuous or bolus infusion of corticosteroids is more appropriate for critically ill patients. Confalonieri et al[@b19-ijgm-6-693] reported that the continuous infusion of hydrocortisone for severe CAP contributed to favorable clinical outcomes.[@b19-ijgm-6-693] In contrast, Mikami et al showed that the bolus infusion of prednisolone for moderate to severe CAP contributed to prompt resolution of clinical symptoms.[@b9-ijgm-6-693] In patients with septic shock, a prospective, randomized study produced by Loisa et al has shown that there were no differences in mortality and vasopressor requirements of patients treated with continuous corticosteroid infusion and those treated with bolus infusion.[@b23-ijgm-6-693] Similarly, a randomized double-blinded trial on ulcerative colitis showed that continuous corticosteroid infusion was not superior to bolus infusion in terms of efficacy and safety.[@b24-ijgm-6-693] In the present study, systemic corticosteroids were administered by bolus infusion to all patients except one. Our study may suggest that the bolus infusion of corticosteroids is appropriate for treating critically ill patients.

Systemic corticosteroids have several undesirable clinical effects, such as immunosuppression, hyperglycemia, and changes of mental condition. These adverse events often make patient care difficult.[@b25-ijgm-6-693]--[@b27-ijgm-6-693] Nevertheless, there are few reports showing severe complications associated with adjunctive systemic corticosteroids in patients with CAP. In their CAP study, Meijvis et al documented that hyperglycemia was more common in patients treated with dexamethasone therapy than in those treated without dexamethasone, but the requirement for additional glucose-lowering therapy did not differ between the groups.[@b8-ijgm-6-693] Similarly, in the present CAP study, the early adjunctive systemic corticosteroids did not bring more adverse events compared with the therapy without early corticosteroids. It is well known that the incidence of significant side effects caused by systemic corticosteroids increases with the dose and duration of administration.[@b28-ijgm-6-693] Low-dose and short-term systemic corticosteroids are administered in most patients with CAP, including the patients in the present study. This type of treatment can be associated with safety of adjunctive systemic corticosteroids in patients with CAP.

We should mention that our current study has several limitations. First, our present study was not a placebo-controlled interventional study. Therefore, the dosage and term of systemic corticosteroids and the antibiotic regimen varied for each patient. However, most of our study cohort received low-dose and short-term systemic corticosteroids, in the same way as in former interventional CAP studies. Additionally, in order to reduce the influence of various confounders as much as possible, we performed the multivariate analysis for assessment of the factors associated with mortality. Second, this study cohort included a limited number of patients because it was a single-center observational study. To demonstrate the clinical impact of early adjunctive systemic corticosteroids for very severe CAP, further multicenter studies including a large number of patients with very severe CAP are needed. Third, adrenocortical function was not evaluated in our study. Although some former studies have shown that relative adrenal insufficiency has little influence on the clinical courses of CAP,[@b9-ijgm-6-693],[@b29-ijgm-6-693],[@b30-ijgm-6-693] we could not exclude the possibility that adjunctive systemic corticosteroids compensated for adrenal insufficiency. Finally, most patients in our study cohort were of advanced age. Therefore, the mortality rate in our present study may have been higher than that in other CAP studies. Although the age did not differ between deceased and surviving patients in our present study, additional studies including critically ill younger patients are needed in order to prove the clinical impact of early adjunctive systemic corticosteroids for very severe CAP.

In conclusion, early adjunctive systemic corticosteroids may be expected to have the efficacy to reduce the mortality in very severe CAP. We can consider the administration of systemic corticosteroids simultaneously with initial antibiotic medication in cases of very severe CAP, although a larger-scale prospective study is necessary.
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![Flow diagram explaining recruitment of study population.\
**Abbreviations:** CAP, community-acquired pneumonia; PSI, pneumonia severity index.](ijgm-6-693Fig1){#f1-ijgm-6-693}

![Kaplan-Meier survival curves in patients treated with and without early adjunctive systemic corticosteroids. No significant difference was observed between both groups (*P* = 0.098).](ijgm-6-693Fig2){#f2-ijgm-6-693}

###### 

Baseline characteristics of enrolled patients

  Characteristics                                                               Values
  ----------------------------------------------------------------------------- ---------------------
  Number                                                                        101
  Age, years                                                                    86 (81--91)
  Male patients                                                                 66 (65.3)
  From nursing home                                                             57 (56.4)
  Performance status                                                            3 (2--3)
  Physical findings on admission                                                
   Systolic blood pressure \<90 mmHg                                            22 (21.8)
   Altered mental status[†](#tfn2-ijgm-6-693){ref-type="table-fn"}              53 (52.5)
   Requirement for high-flow oxygen[‡](#tfn3-ijgm-6-693){ref-type="table-fn"}   51 (50.5)
   Heart rate, per minute                                                       104 (86--116)
  Laboratory findings on admission                                              
   C-reactive protein, mg/dL                                                    12.52 (5.96--23.55)
   Leukocyte count, 10^9^ cells/L                                               11.7 (8.6--14.2)
   Blood urea nitrogen, mg/dL                                                   31.8 (21.3--43.3)
   Albumin, g/dL                                                                3.1 (2.6--3.5)
   Sodium, mEq/L                                                                138 (132--143)
   Glucose, mg/dL                                                               133 (109--174)
   Creatinine, mg/dL                                                            1.01 (0.66--1.51)
   Hematocrit, %                                                                35.4 (30.3--39.2)
   pH of arterial blood                                                         7.41 (7.33--7.47)
   PaCO~2~, mmHg                                                                41.4 (34.1--48.0)
  Radiographic findings on admission                                            
   Bilateral infiltrates                                                        72 (71.3)
   Pleural effusion                                                             38 (37.6)
  Coexisting illnesses                                                          
   Heart failure                                                                25 (24.8)
   Diabetes mellitus                                                            16 (15.8)
   Cerebrovascular diseases                                                     42 (41.6)
   Neoplastic diseases                                                          9 (8.9)
   Chronic kidney diseases                                                      8 (7.9)
   COPD                                                                         11 (10.9)
   Other lung diseases                                                          3 (3.0)
  Pneumonia severity index                                                      152 (139--179)
  Initial antibiotic regimens                                                   
   Antipseudomonal beta-lactams                                                 81 (80.2)
   Fluoroquinolones                                                             14 (13.9)
   Tetracyclines                                                                25 (24.8)
   Clindamycin                                                                  9 (8.9)
  Early adjunctive systemic steroids                                            30 (29.7)
  Clinical outcomes                                                             
   Mortality within 28 days of admission                                        32 (31.7)
   Requirement for intensive care                                               45 (44.6)

**Notes**: Data are expressed as number (%) or median (25th--75th percentile).

Defined as a state of awareness that differed from the normal awareness of each person;

defined as a necessity of oxygen inhalation with mask or mechanical ventilation in order to keep arterial oxygen saturation ≥90%.

**Abbreviations**: COPD, chronic obstructive pulmonary disease; PaCO~2~, partial pressure of carbon dioxide in arterial blood.

###### 

Detected pathogens

  Microorganism                Number
  ---------------------------- -----------
  *Streptococcus pneumoniae*   17 (16.8)
  *Klebsiella pneumoniae*      9 (8.9)
  MRSA                         9 (8.9)
  *Staphylococcus* spp.        8 (7.9)
  *Pseudomonas aeruginosa*     6 (5.9)
  *Escherichia coli*           2 (2.0)
  *Proteus mirabilis*          2 (2.0)
  *Acinetobacter baumannii*    1 (1.0)
  *Enterococcus* spp.          1 (1.0)
  *Serratia marcescens*        1 (1.0)
  Unknown                      45 (44.6)

**Note:** Data are expressed as number (%).

**Abbreviation:** MRSA, methicillin-resistant *Staphylococcus aureus*.

###### 

Dosage and duration of early systemic corticosteroids

                                      Number
  ----------------------------------- --------
  Corticosteroids                     
   Methylprednisolone                 17
   Prednisolone                       12
   Dexamethasone                      1
  Dosage (equivalent to prednisone)   
   20--60 mg/day                      25
   ≥61 mg/day                         5
  Dosing duration                     
   3 days                             6
   4--7 days                          18
   ≥8 days                            6
  Dosing methods                      
   Orally                             0
   Intravenously                      30
    Bolus infusion                    29
    Continuous infusion               1

###### 

Characteristics between patients with and without early systemic steroids

                                                                                Early systemic steroids   Without early steroids   *P*-value
  ----------------------------------------------------------------------------- ------------------------- ------------------------ -----------
  Number                                                                        30                        71                       
  Age, years                                                                    85 (80--90)               86 (81--92)              0.517
  Male patients                                                                 22 (73.3)                 44 (62.0)                0.361
  From nursing home                                                             13 (43.3)                 44 (62.0)                0.124
  Performance status                                                            3 (1--3)                  3 (2--3)                 0.495
  Physical findings on admission                                                                                                   
   Systolic blood pressure \<90 mmHg                                            10 (33.3)                 12 (16.9)                0.111
   Altered mental status[†](#tfn8-ijgm-6-693){ref-type="table-fn"}              24 (80.0)                 29 (40.8)                \<0.001
   Requirement for high-flow oxygen[‡](#tfn9-ijgm-6-693){ref-type="table-fn"}   20 (66.7)                 31 (43.7)                0.049
   Heart rate, per minute                                                       111 (95--123)             100 (83--113)            0.096
  Laboratory findings on admission                                                                                                 
   C-reactive protein, mg/dL                                                    11.65 (5.16--23.18)       13.16 (6.24--23.46)      0.815
   Leukocyte count, 10^9^ cells/L                                               10.4 (6.4--12.7)          12.1 (9.4--16.8)         0.039
   Blood urea nitrogen, mg/dL                                                   32.8 (25.8--40.7)         31.5 (18.9--43.8)        0.499
   Albumin, g/dL                                                                3.3 (3.1--3.7)            3.0 (2.6--3.4)           0.003
   Sodium, meq/L                                                                137 (129--140)            139 (134--145)           0.031
   Glucose, mg/dL                                                               142 (116--155)            132 (106--178)           0.864
   Creatinine, mg/dL                                                            1.06 (0.75--1.91)         0.96 (0.63--1.38)        0.276
   Hematocrit, %                                                                37.1 (32.7--40.4)         35.1 (29.3--38.7)        0.089
   pH of arterial blood                                                         7.37 (7.29--7.46)         7.43 (7.34--7.48)        0.126
   PaCO~2~, mmHg                                                                39.4 (33.9--48.2)         41.7 (34.3--47.8)        0.854
  Radiographic findings on admission                                                                                               
   Bilateral infiltrates                                                        24 (80.0)                 48 (67.6)                0.238
   Pleural effusion                                                             9 (30.0)                  29 (40.8)                0.372
  Coexisting illnesses                                                                                                             
   Heart failure                                                                6 (20.0)                  19 (26.8)                0.616
   Diabetes mellitus                                                            6 (20.0)                  10 (14.1)                0.552
   Cerebrovascular diseases                                                     7 (23.3)                  35 (49.3)                0.017
   Neoplastic diseases                                                          2 (6.7)                   7 (9.9)                  0.722
   Chronic kidney diseases                                                      2 (6.7)                   6 (8.5)                  \>0.999
   COPD                                                                         8 (26.7)                  3 (4.2)                  0.002
   Other lung diseases                                                          3 (10.0)                  0                        0.024
  Pneumonia severity index                                                      149 (141--179)            154 (135--175)           0.629
  Identification of pathogens                                                   20 (66.7)                 36 (50.7)                0.189
   *Streptococcus pneumoniae*                                                   7 (23.3)                  10 (14.1)                0.26
   *Klebsiella pneumoniae*                                                      5 (16.7)                  4 (5.6)                  0.121
   MRSA                                                                         3 (10.0)                  6 (8.5)                  \>0.999
  Initial antibiotic regimens                                                                                                      
   Antipseudomonal beta-lactams                                                 24 (80.0)                 57 (80.3)                \>0.999
   Fluoroquinolones                                                             8 (26.7)                  6 (8.5)                  0.025
   Tetracyclines                                                                8 (26.7)                  17 (23.9)                0.804
   Clindamycin                                                                  1 (3.3)                   8 (11.3)                 0.274
  Clinical outcomes                                                                                                                
   Mortality within 28 days of admission                                        6 (20.0)                  26 (36.6)                0.159
   Requirement for intensive care                                               16 (53.3)                 29 (40.8)                0.279

**Notes:** Data are expressed as number (%) or median (25th--75th percentile).

Defined as a state of awareness that differed from the normal awareness of each person;

defined as a necessity of oxygen inhalation with mask or mechanical ventilation in order to keep arterial oxygen saturation ≥90%.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; MRSA, methicillin-resistant *Staphylococcus aureus*; PaCO~2~, partial pressure of carbon dioxide in arterial blood.

###### 

Adverse events between patients with and without early systemic corticosteroids

                                               Early systemic steroids (n = 30)   Without early steroids (n = 71)   *P*-value
  -------------------------------------------- ---------------------------------- --------------------------------- -----------
  Hyperglycemia with additional intervention   2 (6.7)                            5 (7.0)                           \>0.999
  Confusion                                    6 (20.0)                           6 (8.5)                           0.174
  Nosocomial infection                         2 (6.7)                            5 (7.0)                           \>0.999
  Gastrointestinal bleeding                    0                                  2 (2.8)                           \>0.999

**Note:** Data are expressed as number (%).

###### 

Characteristics between deceased and surviving patients

                                                                                 Deceased              Surviving             *P*-value
  ------------------------------------------------------------------------------ --------------------- --------------------- -----------
  Number                                                                         32                    69                    
  Age, years                                                                     84 (79--89)           86 (82--92)           0.449
  Male patients                                                                  21 (65.6)             45 (65.2)             \>0.999
  From nursing home                                                              18 (56.3)             39 (56.5)             \>0.999
  Performance status                                                             3 (2--3)              3 (2--3)              0.647
  Physical findings on admission                                                                                             
   Systolic blood pressure \<90 mmHg                                             7 (21.9)              15 (21.7)             \>0.999
   Altered mental status[†](#tfn13-ijgm-6-693){ref-type="table-fn"}              20 (62.5)             33 (47.8)             0.202
   Requirement for high-flow oxygen[‡](#tfn14-ijgm-6-693){ref-type="table-fn"}   20 (62.5)             31 (44.9)             0.135
   Heart rate, per minute                                                        105 (94--119)         104 (84--116)         0.571
  Laboratory findings on admission                                                                                           
   C-reactive protein, mg/dL                                                     18.78 (8.60--26.55)   10.79 (4.29--19.86)   0.017
   Leukocyte count, 10^9^ cells/L                                                10.3 (8.7--14.2)      11.9 (8.3--14.2)      0.748
   Blood urea nitrogen, mg/dL                                                    39.8 (24.5--69.1)     31.0 (21.3--40.0)     0.016
   Albumin, g/dL                                                                 2.9 (2.2--3.2)        3.2 (2.8--3.6)        0.005
   Sodium, meq/L                                                                 140 (133--148)        138 (132--141)        0.168
   Glucose, mg/dL                                                                118 (104--171)        138 (110--174)        0.184
   Creatinine, mg/dL                                                             1.19 (0.69--2.04)     0.96 (0.62--1.30)     0.161
   Hematocrit, %                                                                 36.0 (29.5--38.9)     35.1 (30.5--39.5)     0.884
   pH of arterial blood                                                          7.36 (7.33--7.46)     7.43 (7.33--7.45)     0.25
   PaCO~2~, mmHg                                                                 42.0 (35.6--49.9)     41.4 (33.2--48.0)     0.531
  Radiographic findings on admission                                                                                         
   Bilateral infiltrates                                                         26 (81.3)             46 (66.7)             0.16
   Pleural effusion                                                              12 (37.5)             26 (37.7)             \>0.999
  Coexisting illnesses                                                                                                       
   Heart failure                                                                 7 (21.9)              18 (26.1)             0.805
   Diabetes mellitus                                                             6 (18.8)              10 (14.5)             0.572
   Cerebrovascular diseases                                                      12 (37.5)             30 (43.5)             0.666
   Neoplastic diseases                                                           2 (6.3)               7 (10.1)              0.715
   Chronic kidney diseases                                                       3 (9.4)               5 (7.2)               0.706
   COPD                                                                          3 (9.4)               8 (11.6)              \>0.999
   Other lung diseases                                                           1 (3.1)               2 (2.9)               \>0.999
  Pneumonia severity index                                                       163 (147--180)        146 (136--171)        0.071
  Identification of pathogens                                                    21 (65.6)             35 (50.7)             0.199
   *Streptococcus pneumoniae*                                                    4 (12.5)              13 (18.8)             0.571
   *Klebsiella pneumoniae*                                                       1 (3.1)               8 (11.6)              0.266
   MRSA                                                                          6 (18.8)              3 (4.3)               0.027
  Initial antibiotic regimens                                                                                                
   Antipseudomonal beta-lactams                                                  30 (93.8)             51 (73.9)             0.03
   Fluoroquinolones                                                              3 (9.4)               11 (15.9)             0.539
   Tetracyclines                                                                 9 (28.1)              16 (23.2)             0.625
   Clindamycin                                                                   2 (6.3)               7 (10.1)              0.715
  Early adjunctive systemic steroids                                             6 (18.8)              24 (34.8)             0.159
  Requirement for intensive care                                                 25 (78.1)             20 (29.0)             \<0.001

**Notes:** Data are expressed as number (%) or median (25th--75th percentile).

Defined as a state of awareness that differed from the normal awareness of each person;

defined as a necessity of oxygen inhalation with mask or mechanical ventilation in order to keep arterial oxygen saturation ≥90%.

**Abbreviations:** COPD, chronic obstructive pulmonary disease; MRSA, methicillin-resistant *Staphylococcus aureus*; PaCO~2~, partial pressure of carbon dioxide in arterial blood.

###### 

Multivariate analysis for mortality within 28 days of admission

                                                                                 Hazard ratio (95% CI)   *P*-value
  ------------------------------------------------------------------------------ ----------------------- -----------
  Physical findings on admission                                                                         
   Requirement for high-flow oxygen[‡](#tfn16-ijgm-6-693){ref-type="table-fn"}   1.95 (0.63--6.01)       0.246
  Laboratory findings on admission                                                                       
   C-reactive protein                                                            0.99 (0.96--1.03)       0.69
   Blood urea nitrogen                                                           1.02 (1.00--1.04)       0.013
   Albumin                                                                       0.44 (0.22--0.86)       0.017
   Sodium                                                                        0.99 (0.95--1.02)       0.44
   Glucose                                                                       0.99 (0.99--1.00)       0.053
   Creatinine                                                                    0.89 (0.58--1.36)       0.578
  Radiographic findings on admission                                                                     
   Bilateral infiltrates                                                         1.55 (0.48--5.05)       0.466
  Pneumonia severity index                                                       1.00 (0.98--1.02)       0.899
  Identification of pathogens                                                    1.34 (0.54--3.34)       0.527
   MRSA                                                                          2.92 (0.72--11.83)      0.133
  Initial antibiotic regimens                                                                            
   Antipseudomonal beta-lactams                                                  1.39 (0.30--6.46)       0.674
  Early adjunctive systemic steroids                                             0.29 (0.11--0.81)       0.018
  Requirement for intensive care                                                 4.93 (1.75--13.87)      0.003

**Note:**

Defined as a necessity of oxygen inhalation with mask or mechanical ventilation in order to keep arterial oxygen saturation ≥90%.

**Abbreviations:** CI, confidence interval; MRSA, methicillin-resistant *Staphylococcus aureus*.
